Queen Mary Evaluates 4-Gene Oral Cancer Test at 95.5% Accuracy in Under 60 Minutes
Updated
Updated · conexiant.com · Jul 8
Queen Mary Evaluates 4-Gene Oral Cancer Test at 95.5% Accuracy in Under 60 Minutes
3 articles · Updated · conexiant.com · Jul 8
Summary
1,090 brush-biopsy assays from 545 patients showed the qMIDSV3 mRNA test distinguished oral squamous cell carcinoma from low-risk oral lesions with 95.7% sensitivity, 95.1% specificity and 95.5% overall accuracy.
The 4-gene assay delivered results in less than 60 minutes, with an AUC of 0.975 and both false-positive and false-negative rates below 5%.
Queen Mary researchers said the noninvasive brush test is aimed at triage rather than replacing scalpel biopsy, and can be repeated over time without cold-chain storage.
More than 90% of patients with low-risk oral lesions could avoid unnecessary scalpel biopsies if the test is validated for clinical use, offering a faster route to flag cancers needing follow-up.
This painless one-hour test could replace the scalpel. Is it the key to reversing rising oral cancer deaths?
A new oral cancer test boasts 95.5% accuracy. Will it be affordable enough for widespread public screening?
qMIDS-V3 Delivers 95% Accuracy in Non-Invasive Oral Cancer Detection: A Game-Changer for Early, Painless Diagnosis
Overview
Oral cancer is a major global health problem, but current diagnosis relies on invasive scalpel biopsies. While these biopsies are important for early detection and better survival, they have many drawbacks. Most suspicious oral lesions are actually benign, yet patients often undergo painful and unnecessary biopsies, especially on sensitive areas like the tongue. This causes distress, discomfort, and delays in diagnosis. The need for a less invasive, more patient-friendly approach is clear. The report highlights how these challenges drive the search for better diagnostic solutions that can improve patient experience and outcomes.